Nuvilex Inc (OTCMKTS:NVLX) surges further on positive medical marijuana legislation

Boston, MA, 05/07/2013 - Call it a hype or a real catalyst, the recent approval of a medical marijuana program for companies like Nuvilex that have business lines focused on medical marijuana research is having a major impact on the stocks. Nuvilex Inc. (OTCQB:NVLX) could be positioned as a beneficiary of the State of Maryland becoming the 19th state in the U.S. to approve a medical marijuana program.

 So what does NVLX provide ? Nuvilex is an international firm engaged in live-cell encapsulation technology to treat pancreatic cancer along with the development and study of the use of medical marijuana for the treatment of oncology patients.

 As per a recent report issued by Goldman Small Cap Research, as each state in the U.S. passes medical marijuana legislation, the size of the industry dramatically grows. In particular, adding Maryland to the mix is a major plus for Nuvilex since it is headquartered in Silver Spring, Maryland. Moreover, the state is a hotbed of medical research for not just the region but the entire nation due to access to world-class medical research institutions such as Johns Hopkins University and the National Institute of Health.

 The series of press releases issued by NVLX were coupled by a major stock awareness program launched by PremiereStockAlerts.com that is helping spread the word. The program started on April 23rd and since then NVLX has doubled from 0.06 to 0.13. Looking at the recent trading pattern it seems NVLX could be very week on the verge of a breakout.

About Nuvilex, Inc. (OTCQB: NVLX): Nuvilex, Inc. has been a provider of all-natural products for many years, has expanded its company to increase its natural product based footprint through medical marijuana studies and is becoming an international biotechnology provider of live, therapeutically valuable, encapsulated cells and services for treatments, research and medicine. The Company’s offerings will ultimately include cancer, diabetes and other clinical treatments using the company’s natural product knowledge, product base, cell and gene therapy expertise, and live-cell encapsulation technology in addition to other new products currently under development. For more information visit: www.nuvilex.com.